Personalized Oncology
Introduction to Onco-PDO®
Onco-PDO® (Patient-Derived Organoids) is an advanced, personalized oncology testing service designed to optimize cancer treatment. By using patient-derived tumor samples to culture 3D organoids, Onco-PDO® enables comprehensive drug sensitivity testing, providing critical insights into the most effective therapeutic options for individual patients. This tailored approach to treatment selection helps reduce unnecessary side effects arising from ineffective treatment identified in the report and improves the likelihood of positive patient outcomes.
Leveraging PDOs, Onco-PDO® offers a robust platform for real-time drug sensitivity assessment, allowing oncologists to make evidence-based treatment decisions tailored to each patient's cancer profile. This innovative test not only enhances personalized cancer care but also aligns with advancements in precision oncology, integrating cutting-edge technology and clinical expertise to deliver optimal therapeutic solutions.
Benefits from Onco-PDO® test
Onco-PDO® can help you receive the unique treatment you deserve, and this could make all the difference.
Onco-PDO® Test is CE marked according to IVD Directive 98/79/EC.
How does the Onco-PDO® test work?
Your tumor cells will grow as mini organ in a 3-Dimensional culture called PDOs (Patient-Derived-Organoids). The chemotherapeutic drugs selected by your oncologist will be tested on your individual mini organ (PDOs) in the Invitrocue laboratory. The response of each individual treatment will be analyzed, and the report will be provided to your oncologist in a clinically relevant time frame.
Is the Onco-PDO® test suitable for me?
The Onco-PDO® test can be performed for all solid tumors, including but not limited to breast, ovarian, lung, colorectal, pancreatic, and gastric cancers, as well as rare cancer types. We are continuously working on expanding the test to cover additional cancer types.
This test is intended for patients undergoing drug treatment, whether they are at an early stage, end stage, or experiencing a relapse. It is also beneficial for relapsed patients who have not responded to previous therapies.
Early stage HER2 positive Breast cancer
HER2 DAPI
Stage IV ER positive Breast cancer
ER E-cad DAPI
Stage IV ER positive Breast cancer
ER E-cad DAPI
Stage IV ER positive Breast cancer
ER E-cad
How does the Onco-PDO® test work?
Every cancer is unique, shaped by a combination of genetic factors, environmental influences, and specific tumor characteristics. For example, from the organoid images, although they are all breast cancer samples, each one exhibits different morphology and receptor status, which highlights the variability even within the same type of cancer. These differences mean that a treatment that works for one patient may not be effective for another.
The Onco-PDO® test addresses this challenge by tailoring treatment to the individual patient's tumor. By testing how a patient’s specific tumor cells respond to various drugs, Onco-PDO® provides a personalized approach to cancer treatment. This ensures that patients receive the most effective therapies for their unique cancer profile, leading to better outcomes, reduced side effects, and a more efficient use of time and resources. This level of customization is crucial in delivering the best possible care, particularly when dealing with the complexities of cancer.
Where can the Onco-PDO® test be performed?
The Onco-PDO® test is available through hospitals and oncologists in Malaysia. Simply ask your treating oncologist about it.
Additionally, the test is also offered in Singapore, Thailand, Korea, China, Hong Kong, Germany, Spain, Australia, Brazil, and the USA. Drug testing is conducted in our high-standard laboratories located in Munich/Germany, Hong Kong, Singapore, and soon in Malaysia and São Paulo/Brazil.
We welcome all inquiries.
Scientific research and development
With our international team, we constantly monitor our quality through clinical studies. Get in contact with our scientists to learn more about it.
This test has been developed in collaboration with A*STAR’s Genome Institute of Singapore, a world leading institution in functional genomics and integrative biology. The technology supporting the test has been published in peer-reviewed journals like Nature Communications and Nature Medicine.
